|
Miscellaneous
articles
Digitized
mammography: a clinical trial of postmenopausal women randomly
assigned to receive raloxifene, estrogen, or placebo.
Freedman M, San Martin J, O'Gorman J, et al. J Natl Cancer
Inst. 93(1):51-56, 2001 Jan 3.
Silencing
and reactivation of the selective estrogen receptor modulator-estrogen
receptor alpha complex.
Liu H, Lee ES, Deb Los Reyes A, Zapf JW, Jordan VC. Cancer
Res. 2001;61:3632-9.
Tumor
variants by hormone receptor expression in white patients
with node-negative breast cancer from the surveillance, epidemiology,
and end results database.
Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA.
Journal of Clinical Oncology. 19(1):18-27, 2001 Jan 1.
Estrogen
and antiestrogen actions on transforming growth factorbeta
(Tgfbeta) in normal human breast epithelial (HBE) cells.
Malet C, Fibleuil F, Mestayer C, Mowszowicz I, Kuttenn F.
Mol Cell Endocrinol. 2001;174:21-30.
Antiestrogens,
Tamoxifen
Scottish
adjuvant Tamoxifen trial: a randomized study updated to 15
years.
Stewart HJ, Prescott RJ, Forrest AP. J Natl Cancer Inst. 2001;93:456-62.
Mechanism
of lower genotoxicity of toremifene compared with Tamoxifen.
Shibutani S, Ravindernath A, Terashima I, et al. Cancer Res.
2001;61:3925-31.
Preliminary
assessment of cognitive function in breast cancer patients
treated with Tamoxifen.
Paganini-Hill
A, Clark LJ. Breast Cancer Res Treat. 2001;64:165-76.
Understanding
the genotoxicity of Tamoxifen?
Phillips DH. Carcinogenesis. 2001;22:839-849.
Tamoxifen-induced
hypertriglyceridemia in association with diabetes mellitus.
Milionis
HJ, Liberopoulos EN, Elisaf MS. Diabetes Metab. 2001;27:160-3.
Prospective
study on gynaecological effects of two antioestrogens Tamoxifen
and toremifene in postmenopausal women.
Marttunen
MB, Cacciatore B, Hietanen P, et alBr J Cancer. 2001;84:897-902.
Interaction
of phytoestrogens with estrogen receptors alpha and beta.
Morito K, Hirose T, Kinjo J, et al. Biol Pharm Bull. 2001;24:351-6.
Phase
I study of a third-generation selective estrogen receptor
modulator, LY353381.HCL, in metastatic breast cancer.
Munster PN, Buzdar A, Dhingra K, et al. J Clin Oncol. 2001;19:2002-9.
Flexible
estrogen receptor modulators: design, synthesis, and antagonistic
effects in human MCF-7 breast cancer cells.
Meegan MJ, Hughes RB, Lloyd DG, Williams DC, Zisterer DM.
J Med Chem. 2001;44:1072-84.
Tamoxifen-induced
antitumorigenic/antiestrogenic action synergized by a selective
aryl hydrocarbon receptor modulator.
McDougal A, Wormke M, Calvin J, Safe S. Cancer Res. 2001;61:3902-7.
Tamoxifen
and chemotherapy for axillary node-negative, estrogen receptor-negative
breast cancer: Findings from National Surgical Adjuvant Breast
and Bowel Project B-23.
Fisher B, Anderson S, Tan-Chiu E, et al. Journal of Clinical
Oncology. 19(4):931-942, 2001 Feb 15.
Adjuvant
Tamoxifen: Predictors of use, side effects, and discontinuation
in older women.
Demissie S, Silliman RA, Lash TL. Journal of Clinical Oncology.
19(2):322-328, 2001 Jan 15.
Tamoxifen-failed
male breast cancer with a high level of circulating estrogen:
Report of a case.
Takei
H, Iino Y, Horiguchi J, et al.
Surgery Today-The Japanese Journal of Surgery. 31(2):149-151,
2001.
Phosphatidylinositol
3-kinase/AKT-mediated activation of estrogen receptor alpha:
a new model for anti-estrogen resistance.
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D,
Ali S, Nakshatri H. J Biol Chem. 2001;276:9817-24.
Circumventing
Tamoxifen resistance in breast cancers using antiestrogens
that induce unique conformational changes in the estrogen
receptor.
Connor CE, Norris JD, Broadwater G, et al. Cancer Res. 2001;61:2917-22.
Five
versus more than five years of Tamoxifen for lymph node-negative
breast cancer: updated findings from the National Surgical
Adjuvant Breast and Bowel Project B-14 randomized trial.
Fisher B, Dignam J, Bryant J, Wolmark N. J Natl Cancer Inst.
2001;93:684-90.
Phase
I clinical trial of alitretinoin and Tamoxifen in breast cancer
patients: toxicity, pharmacokinetic, and biomarker evaluations.
Lawrence
JA, Adamson PC, Caruso R, et al. J Clin Oncol. 2001;19:2754-63.
Tamoxifen
treatment and gynecologic side effects: a review.
Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema
H, Van der Zee AG. Obstet Gynecol. 2001;97:855-66.
Aromatase
Inhibitors
Superior
efficacy of letrozole versus Tamoxifen as first-line therapy
for postmenopausal women with advanced breast cancer: results
of a phase iii study of the international letrozole breast
cancer group.
Mouridsen H, Gershanovich M, Sun Y, et al. J Clin Oncol. 2001;19:2596-606.
Pharmacokinetics
and metabolism of formestane in breast cancer patients.
Lonning PE, Geisler J, Johannessen DC, et al. J Steroid Biochem
Mol Biol. 2001;77:39-47.
Aromatase
inhibitors in the treatment and prevention of breast cancer
[Review].
Goss PE, Strasser K. Journal of Clinical Oncology. 19(3):881-894,
2001 Feb 1.
Efficacy
of levormeloxifene in the prevention of postmenopausal bone
loss and on the lipid profile compared to low dose hormone
replacement therapy.
Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen
C. Journal of Clinical Endocrinology & Metabolism. 86(2):755-760,
2001 Feb.
Influence
of neoadjuvant anastrozole (arimidex) on intratumoral estrogen
levels and proliferation markers in patients with locally
advanced breast cancer.
Geisler J, Detre S, Berntsen H, et al. Clin Cancer Res. 2001;7:1230-6.
Faslodex®
(fulvestrant, ICI182180): An estrogen receptor downregulator
No
new publications
Ovarian
ablation/suppression
No
new publications
Estrogen/progesterone
receptors
No
new publications
|
